Venus Remedies has entered into an exclusive license agreement with lnfex Therapeutics, a UK-based anti-infectives specialist for the clinical development of MET-X. This agreement authorizes the company to spearhead the clinical development, registration, and commercialization of MET-X, an innovative Metallo-Beta-Lactamase (MBL) inhibitor. The initial development phase will focus on integrating MET-X with meropenem to tackle drug-resistant Gram-negative bacteria, with the company holding exclusive marketing rights within India.
Under the terms of the agreement, the company will commence with a Phase I involving healthy volunteers in India, evaluating MET-X in combination with meropenem. Following successful Phase I outcome, the focus will shift to Phase II/III trials targeting drug-resistant Complicated Urinary Tract Infections (cUTls), prevalent in hospital settings.
This strategic move is aligned with the company’s extensive experience in antibiotic R&D and critical care, enhancing its leadership in Indian critical care landscape. The company’s formidable position in meropenem marketing and manufacturing will facilitate the integration of MET-X in existing and prospective antibiotic strategies.
Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.
